The Association for Clinical Quantum is pleased to join the Quantum + AI Tech Show 2026 as an event partner and will work with Health AI Insiders as a media partner. The show takes place on Wednesday 4 November 2026 at Big Penny Social, 1 Priestley Way, London E17 6AL. It brings together leaders from industry, healthcare, government, research and investment to examine where quantum and AI may deliver practical value.
For the Association, this is a chance to put clinical questions, patient safety and responsible evidence at the centre of the discussion. Healthcare adoption cannot be driven by technical novelty alone. Every application must start with a clear clinical problem, be tested against strong classical alternatives and be reported with honest limitations. This reflects the show’s message: “No hype. Just results.”
An independent clinical quantum think tank
The Association is an independent think tank supporting NHS clinicians and healthcare innovators exploring quantum technologies. It is not a membership organisation, regulator, accrediting body or NHS authority, and it does not claim endorsement by the NHS, a provider or a vendor.
It aims to improve clinical quantum literacy and help teams ask better questions before committing time, data or resources. Its principle is simple: the clinical problem comes first and quantum remains optional. If a classical method proves safer, faster or cheaper, publishing that is progress, not failure.
Clinical Quantum Methodology: problem first, quantum second
The Clinical Quantum Methodology (CQM) starts by defining the clinical question in plain language. Only then does it ask whether a quantum method is relevant. Teams must establish data provenance, set success and failure criteria in advance, run a classical comparison first and document the engine used in every experiment. Simulation, emulation and physical hardware are separate evidence tiers and are never interchangeable.
Negative, blocked and inconclusive findings count as legitimate results. Research programmes such as EndoTrack and Quantum Health Signals have helped sharpen this discipline. They are research environments and do not establish clinical efficacy, deployment readiness or patient benefit.
Clinical Quantum Advantage: a test, not a slogan
Clinical Quantum Advantage (CQA) asks whether a quantum approach gives meaningful value for a defined clinical task. It does not assume an advantage exists. A positive claim must exceed experimental uncertainty, address a real limitation of the best classical approach and have a credible cost case.
CQA separates two questions: did the mechanism work, and did it provide an advantage? A yes to the first does not mean a yes to the second. This keeps “advantage” an evidence standard, not a marketing label.
QUOPS: measuring hardware capability without confusing it with clinical value
A September 2026 paper by Proctor and colleagues introduced QUOPS, a way to measure the size of circuits a quantum system can run successfully and how fast. It was applied to systems from Quantinuum, Google and IBM. The paper reports that problems such as RSA-2048 factoring remain about five orders of magnitude beyond current capability.
For the Association, QUOPS is external literature. It does not validate CQRS, show clinical quantum advantage or establish readiness for an NHS use case. Its value is a clearer vocabulary for reporting what hardware has actually executed.
Read Proctor et al., Benchmarking the computational power of quantum computers.
Exploring social prescribing responsibly
The Quantum Social Prescribing Methodology (QSPM) is an emerging research framework. It explores whether quantum or quantum-inspired approaches can help with questions in social prescribing systems, while keeping clinical judgement and community knowledge first. It is not a validated intervention, decision tool or deployed service.
Measuring readiness without hiding uncertainty
The Clinical Quantum Readiness Scale (CQRS), now version 1.5, rates readiness on two separate 0 to 10 scales. The value axis asks whether quantum adds measured value. The verification axis asks whether the evidence can be trusted and independently checked. The two scores are always reported as a pair and never averaged.
Levels change only after a real evidence event, such as traceable data, a pre-registered protocol or an external review. A new publication cannot raise a score by itself. CQRS v1.5 uses QUOPS for capability reporting only, not as programme evidence.
Why this partnership matters
Clinicians should help define the questions, evidence thresholds and safety boundaries before quantum technologies mature. At the show, the Association will bring a clinical view grounded in practical use cases and transparent evaluation. Health AI Insiders will help share it with a wider health-innovation audience.
The Association welcomes conversations with clinicians, researchers, founders, safety professionals and technology teams interested in evidence-led clinical quantum work.
Learn more at clinicalquantum.com.
